225 related articles for article (PubMed ID: 16601280)
1. Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas.
de Sá SV; Corrêa-Giannella ML; Machado MC; de Souza JJ; Pereira MA; Patzina RA; Siqueira SA; Machado MC; Giannella-Neto D
Endocr Relat Cancer; 2006 Mar; 13(1):69-78. PubMed ID: 16601280
[TBL] [Abstract][Full Text] [Related]
2. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.
Kubota A; Yamada Y; Kagimoto S; Shimatsu A; Imamura M; Tsuda K; Imura H; Seino S; Seino Y
J Clin Invest; 1994 Mar; 93(3):1321-5. PubMed ID: 8132773
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1--5 and correlation with receptor protein expression and tumor pathology.
Kumar U; Grigorakis SI; Watt HL; Sasi R; Snell L; Watson P; Chaudhari S
Breast Cancer Res Treat; 2005 Jul; 92(2):175-86. PubMed ID: 15986128
[TBL] [Abstract][Full Text] [Related]
4. Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction.
Murabe H; Shimatsu A; Ihara C; Mizuta H; Nakamura Y; Nagata I; Kikuchi H; Nakao K
J Neuroendocrinol; 1996 Aug; 8(8):605-10. PubMed ID: 8866248
[TBL] [Abstract][Full Text] [Related]
5. Deficiency of somatostatin (SST) receptor type 5 (SSTR5) is associated with sexually dimorphic changes in the expression of SST and SST receptors in brain and pancreas.
Ramírez JL; Grant M; Norman M; Wang XP; Moldovan S; de Mayo FJ; Brunicardi C; Kumar U
Mol Cell Endocrinol; 2004 Jun; 221(1-2):105-19. PubMed ID: 15223137
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor subtype gene expression in pituitary adenomas.
Miller GM; Alexander JM; Bikkal HA; Katznelson L; Zervas NT; Klibanski A
J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling in insulinomas of Men1 beta-cell mutant mice reveals early genetic and epigenetic events involved in pancreatic beta-cell tumorigenesis.
Fontanière S; Tost J; Wierinckx A; Lachuer J; Lu J; Hussein N; Busato F; Gut I; Wang ZQ; Zhang CX
Endocr Relat Cancer; 2006 Dec; 13(4):1223-36. PubMed ID: 17158767
[TBL] [Abstract][Full Text] [Related]
8. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.
Zatelli MC; Piccin D; Vignali C; Tagliati F; Ambrosio MR; Bondanelli M; Cimino V; Bianchi A; Schmid HA; Scanarini M; Pontecorvi A; De Marinis L; Maira G; degli Uberti EC
Endocr Relat Cancer; 2007 Mar; 14(1):91-102. PubMed ID: 17395978
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression.
Corbetta S; Ballaré E; Mantovani G; Lania A; Losa M; Di Blasio AM; Spada A
Eur J Clin Invest; 2001 Mar; 31(3):208-14. PubMed ID: 11264647
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin regulates somatostatin receptor subtype mRNA expression in GH3 cells.
Bruno JF; Xu Y; Berelowitz M
Biochem Biophys Res Commun; 1994 Aug; 202(3):1738-43. PubMed ID: 7914724
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.
Butturini G; Bettini R; Missiaglia E; Mantovani W; Dalai I; Capelli P; Ferdeghini M; Pederzoli P; Scarpa A; Falconi M
Endocr Relat Cancer; 2006 Dec; 13(4):1213-21. PubMed ID: 17158766
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours.
Jaïs P; Terris B; Ruszniewski P; LeRomancer M; Reyl-Desmars F; Vissuzaine C; Cadiot G; Mignon M; Lewin MJ
Eur J Clin Invest; 1997 Aug; 27(8):639-44. PubMed ID: 9279525
[TBL] [Abstract][Full Text] [Related]
13. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.
Bertherat J; Tenenbaum F; Perlemoine K; Videau C; Alberini JL; Richard B; Dousset B; Bertagna X; Epelbaum J
J Clin Endocrinol Metab; 2003 Nov; 88(11):5353-60. PubMed ID: 14602773
[TBL] [Abstract][Full Text] [Related]
15. Expression and functional consequences of oestrogen and progesterone receptors in human insulinomas.
Alabraba EB; Taniere P; Reynolds GM; Stewart PM; Wigmore SJ; Bramhall SR
Endocr Relat Cancer; 2007 Dec; 14(4):1081-8. PubMed ID: 18045959
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical somatostatin receptor expression in insulinomas.
Peltola E; Vesterinen T; Leijon H; Hannula P; Huhtala H; Mäkinen M; Nieminen L; Pirinen E; Rönty M; Söderström M; Arola J; Jaatinen P
APMIS; 2023 Apr; 131(4):152-160. PubMed ID: 36680557
[TBL] [Abstract][Full Text] [Related]
17. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas.
Jaquet P; Ouafik L; Saveanu A; Gunz G; Fina F; Dufour H; Culler MD; Moreau JP; Enjalbert A
J Clin Endocrinol Metab; 1999 Sep; 84(9):3268-76. PubMed ID: 10487698
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas - predominance of receptor subtype 4.
Portela-Gomes GM; Stridsberg M; Grimelius L; Rorstad O; Janson ET
Endocr Pathol; 2007; 18(2):79-85. PubMed ID: 17916997
[TBL] [Abstract][Full Text] [Related]
19. Co-expression of ghrelin and its receptor in pancreatic endocrine tumours.
Ekeblad S; Lejonklou MH; Grimfjärd P; Johansson T; Eriksson B; Grimelius L; Stridsberg M; Stålberg P; Skogseid B
Clin Endocrinol (Oxf); 2007 Jan; 66(1):115-22. PubMed ID: 17201810
[TBL] [Abstract][Full Text] [Related]
20. Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas.
Padova H; Rubinfeld H; Hadani M; Cohen ZR; Nass D; Taylor JE; Culler MD; Shimon I
Mol Cell Endocrinol; 2008 May; 286(1-2):214-8. PubMed ID: 18276067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
